CN112226905A - Preparation process and application of spunbonded non-woven fabric containing honeysuckle antipyretic - Google Patents
Preparation process and application of spunbonded non-woven fabric containing honeysuckle antipyretic Download PDFInfo
- Publication number
- CN112226905A CN112226905A CN202011061798.2A CN202011061798A CN112226905A CN 112226905 A CN112226905 A CN 112226905A CN 202011061798 A CN202011061798 A CN 202011061798A CN 112226905 A CN112226905 A CN 112226905A
- Authority
- CN
- China
- Prior art keywords
- parts
- honeysuckle
- woven fabric
- powder
- antipyretic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000004745 nonwoven fabric Substances 0.000 title claims abstract description 48
- 241000205585 Aquilegia canadensis Species 0.000 title claims abstract description 40
- 230000001754 anti-pyretic effect Effects 0.000 title claims abstract description 35
- 239000002221 antipyretic Substances 0.000 title claims abstract description 35
- 238000002360 preparation method Methods 0.000 title claims description 14
- 239000000843 powder Substances 0.000 claims abstract description 29
- 238000000034 method Methods 0.000 claims abstract description 20
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims abstract description 18
- 239000002994 raw material Substances 0.000 claims abstract description 16
- 239000000341 volatile oil Substances 0.000 claims abstract description 14
- 239000004743 Polypropylene Substances 0.000 claims abstract description 12
- 230000008569 process Effects 0.000 claims abstract description 12
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 10
- 239000000463 material Substances 0.000 claims abstract description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 10
- 229920002261 Corn starch Polymers 0.000 claims abstract description 9
- 229920002367 Polyisobutene Polymers 0.000 claims abstract description 9
- 229910000019 calcium carbonate Inorganic materials 0.000 claims abstract description 9
- 239000008120 corn starch Substances 0.000 claims abstract description 9
- -1 polypropylene Polymers 0.000 claims abstract description 9
- 229920001155 polypropylene Polymers 0.000 claims abstract description 9
- 239000011812 mixed powder Substances 0.000 claims abstract description 8
- 238000003756 stirring Methods 0.000 claims abstract description 8
- 238000001125 extrusion Methods 0.000 claims abstract description 7
- 206010035148 Plague Diseases 0.000 claims abstract description 5
- 238000001816 cooling Methods 0.000 claims abstract description 4
- 238000005469 granulation Methods 0.000 claims abstract description 4
- 230000003179 granulation Effects 0.000 claims abstract description 4
- 238000007731 hot pressing Methods 0.000 claims abstract description 4
- 238000005098 hot rolling Methods 0.000 claims abstract description 4
- 239000007788 liquid Substances 0.000 claims abstract description 4
- 238000002156 mixing Methods 0.000 claims abstract description 4
- 229920000742 Cotton Polymers 0.000 claims abstract description 3
- 239000003814 drug Substances 0.000 claims description 24
- 229940079593 drug Drugs 0.000 claims description 19
- 230000001681 protective effect Effects 0.000 claims description 14
- 230000000694 effects Effects 0.000 claims description 13
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 239000004753 textile Substances 0.000 claims description 7
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims description 6
- 244000144725 Amygdalus communis Species 0.000 claims description 6
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims description 6
- 241000218671 Ephedra Species 0.000 claims description 6
- 244000303040 Glycyrrhiza glabra Species 0.000 claims description 6
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 6
- 240000000691 Houttuynia cordata Species 0.000 claims description 6
- 235000013719 Houttuynia cordata Nutrition 0.000 claims description 6
- 206010061218 Inflammation Diseases 0.000 claims description 6
- 240000002505 Pogostemon cablin Species 0.000 claims description 6
- 235000011751 Pogostemon cablin Nutrition 0.000 claims description 6
- 235000003893 Prunus dulcis var amara Nutrition 0.000 claims description 6
- 244000042430 Rhodiola rosea Species 0.000 claims description 6
- 235000003713 Rhodiola rosea Nutrition 0.000 claims description 6
- 241000607479 Yersinia pestis Species 0.000 claims description 6
- 238000009792 diffusion process Methods 0.000 claims description 6
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 6
- 229910052602 gypsum Inorganic materials 0.000 claims description 6
- 239000010440 gypsum Substances 0.000 claims description 6
- 235000011477 liquorice Nutrition 0.000 claims description 6
- 229940041616 menthol Drugs 0.000 claims description 6
- 239000002245 particle Substances 0.000 claims description 6
- 241000894006 Bacteria Species 0.000 claims description 5
- 230000004054 inflammatory process Effects 0.000 claims description 4
- 241000196133 Dryopteris Species 0.000 claims description 3
- 241000196131 Dryopteris filix-mas Species 0.000 claims description 3
- 241000334160 Isatis Species 0.000 claims description 3
- 240000004980 Rheum officinale Species 0.000 claims description 3
- 235000008081 Rheum officinale Nutrition 0.000 claims description 3
- 241000700605 Viruses Species 0.000 claims description 3
- 239000010231 banlangen Substances 0.000 claims description 3
- 239000000835 fiber Substances 0.000 claims description 3
- 239000012530 fluid Substances 0.000 claims description 3
- 239000002105 nanoparticle Substances 0.000 claims description 3
- 238000009987 spinning Methods 0.000 claims description 3
- 229920000642 polymer Polymers 0.000 abstract description 9
- 238000012545 processing Methods 0.000 abstract description 5
- 238000009739 binding Methods 0.000 abstract 1
- 239000008187 granular material Substances 0.000 abstract 1
- 238000003825 pressing Methods 0.000 abstract 1
- 238000005096 rolling process Methods 0.000 abstract 1
- 238000007493 shaping process Methods 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 15
- 241001465754 Metazoa Species 0.000 description 14
- 239000000047 product Substances 0.000 description 14
- 230000008961 swelling Effects 0.000 description 13
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 11
- 230000000844 anti-bacterial effect Effects 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 10
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 10
- 229960003957 dexamethasone Drugs 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 8
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 8
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 230000003110 anti-inflammatory effect Effects 0.000 description 7
- 230000000840 anti-viral effect Effects 0.000 description 7
- 239000002158 endotoxin Substances 0.000 description 7
- 239000000284 extract Substances 0.000 description 7
- 229920006008 lipopolysaccharide Polymers 0.000 description 7
- 239000008096 xylene Substances 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 241000282414 Homo sapiens Species 0.000 description 5
- 238000002386 leaching Methods 0.000 description 5
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 4
- 241000711573 Coronaviridae Species 0.000 description 4
- 206010014025 Ear swelling Diseases 0.000 description 4
- 208000038016 acute inflammation Diseases 0.000 description 4
- 230000006022 acute inflammation Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 230000035622 drinking Effects 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 238000004659 sterilization and disinfection Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000003385 bacteriostatic effect Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 210000005069 ears Anatomy 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 241000222122 Candida albicans Species 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 241000227287 Elliottia pyroliflora Species 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000628997 Flos Species 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 240000001307 Myosotis scorpioides Species 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 230000002155 anti-virotic effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 229940095731 candida albicans Drugs 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010069767 H1N1 influenza Diseases 0.000 description 1
- 244000048199 Hibiscus mutabilis Species 0.000 description 1
- 235000003973 Hibiscus mutabilis Nutrition 0.000 description 1
- 241000712431 Influenza A virus Species 0.000 description 1
- 102000002397 Kinins Human genes 0.000 description 1
- 108010093008 Kinins Proteins 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000269982 Paralichthys Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 238000002832 anti-viral assay Methods 0.000 description 1
- 238000000222 aromatherapy Methods 0.000 description 1
- 208000037979 autoimmune inflammatory disease Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000000556 factor analysis Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 239000009929 lianhuaqingwen Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 238000001422 normality test Methods 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 201000010740 swine influenza Diseases 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- D—TEXTILES; PAPER
- D04—BRAIDING; LACE-MAKING; KNITTING; TRIMMINGS; NON-WOVEN FABRICS
- D04H—MAKING TEXTILE FABRICS, e.g. FROM FIBRES OR FILAMENTARY MATERIAL; FABRICS MADE BY SUCH PROCESSES OR APPARATUS, e.g. FELTS, NON-WOVEN FABRICS; COTTON-WOOL; WADDING ; NON-WOVEN FABRICS FROM STAPLE FIBRES, FILAMENTS OR YARNS, BONDED WITH AT LEAST ONE WEB-LIKE MATERIAL DURING THEIR CONSOLIDATION
- D04H1/00—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres
- D04H1/40—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres from fleeces or layers composed of fibres without existing or potential cohesive properties
- D04H1/54—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres from fleeces or layers composed of fibres without existing or potential cohesive properties by welding together the fibres, e.g. by partially melting or dissolving
- D04H1/541—Composite fibres, e.g. sheath-core, sea-island or side-by-side; Mixed fibres
-
- D—TEXTILES; PAPER
- D01—NATURAL OR MAN-MADE THREADS OR FIBRES; SPINNING
- D01F—CHEMICAL FEATURES IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS; APPARATUS SPECIALLY ADAPTED FOR THE MANUFACTURE OF CARBON FILAMENTS
- D01F1/00—General methods for the manufacture of artificial filaments or the like
- D01F1/02—Addition of substances to the spinning solution or to the melt
- D01F1/10—Other agents for modifying properties
-
- D—TEXTILES; PAPER
- D01—NATURAL OR MAN-MADE THREADS OR FIBRES; SPINNING
- D01F—CHEMICAL FEATURES IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS; APPARATUS SPECIALLY ADAPTED FOR THE MANUFACTURE OF CARBON FILAMENTS
- D01F1/00—General methods for the manufacture of artificial filaments or the like
- D01F1/02—Addition of substances to the spinning solution or to the melt
- D01F1/10—Other agents for modifying properties
- D01F1/103—Agents inhibiting growth of microorganisms
-
- D—TEXTILES; PAPER
- D01—NATURAL OR MAN-MADE THREADS OR FIBRES; SPINNING
- D01F—CHEMICAL FEATURES IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS; APPARATUS SPECIALLY ADAPTED FOR THE MANUFACTURE OF CARBON FILAMENTS
- D01F8/00—Conjugated, i.e. bi- or multicomponent, artificial filaments or the like; Manufacture thereof
- D01F8/04—Conjugated, i.e. bi- or multicomponent, artificial filaments or the like; Manufacture thereof from synthetic polymers
- D01F8/06—Conjugated, i.e. bi- or multicomponent, artificial filaments or the like; Manufacture thereof from synthetic polymers with at least one polyolefin as constituent
-
- D—TEXTILES; PAPER
- D01—NATURAL OR MAN-MADE THREADS OR FIBRES; SPINNING
- D01F—CHEMICAL FEATURES IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS; APPARATUS SPECIALLY ADAPTED FOR THE MANUFACTURE OF CARBON FILAMENTS
- D01F8/00—Conjugated, i.e. bi- or multicomponent, artificial filaments or the like; Manufacture thereof
- D01F8/18—Conjugated, i.e. bi- or multicomponent, artificial filaments or the like; Manufacture thereof from other substances
-
- D—TEXTILES; PAPER
- D04—BRAIDING; LACE-MAKING; KNITTING; TRIMMINGS; NON-WOVEN FABRICS
- D04H—MAKING TEXTILE FABRICS, e.g. FROM FIBRES OR FILAMENTARY MATERIAL; FABRICS MADE BY SUCH PROCESSES OR APPARATUS, e.g. FELTS, NON-WOVEN FABRICS; COTTON-WOOL; WADDING ; NON-WOVEN FABRICS FROM STAPLE FIBRES, FILAMENTS OR YARNS, BONDED WITH AT LEAST ONE WEB-LIKE MATERIAL DURING THEIR CONSOLIDATION
- D04H1/00—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres
- D04H1/40—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres from fleeces or layers composed of fibres without existing or potential cohesive properties
- D04H1/54—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres from fleeces or layers composed of fibres without existing or potential cohesive properties by welding together the fibres, e.g. by partially melting or dissolving
- D04H1/558—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres from fleeces or layers composed of fibres without existing or potential cohesive properties by welding together the fibres, e.g. by partially melting or dissolving in combination with mechanical or physical treatments other than embossing
-
- D—TEXTILES; PAPER
- D04—BRAIDING; LACE-MAKING; KNITTING; TRIMMINGS; NON-WOVEN FABRICS
- D04H—MAKING TEXTILE FABRICS, e.g. FROM FIBRES OR FILAMENTARY MATERIAL; FABRICS MADE BY SUCH PROCESSES OR APPARATUS, e.g. FELTS, NON-WOVEN FABRICS; COTTON-WOOL; WADDING ; NON-WOVEN FABRICS FROM STAPLE FIBRES, FILAMENTS OR YARNS, BONDED WITH AT LEAST ONE WEB-LIKE MATERIAL DURING THEIR CONSOLIDATION
- D04H3/00—Non-woven fabrics formed wholly or mainly of yarns or like filamentary material of substantial length
- D04H3/08—Non-woven fabrics formed wholly or mainly of yarns or like filamentary material of substantial length characterised by the method of strengthening or consolidating
- D04H3/14—Non-woven fabrics formed wholly or mainly of yarns or like filamentary material of substantial length characterised by the method of strengthening or consolidating with bonds between thermoplastic yarns or filaments produced by welding
- D04H3/147—Composite yarns or filaments
-
- D—TEXTILES; PAPER
- D10—INDEXING SCHEME ASSOCIATED WITH SUBLASSES OF SECTION D, RELATING TO TEXTILES
- D10B—INDEXING SCHEME ASSOCIATED WITH SUBLASSES OF SECTION D, RELATING TO TEXTILES
- D10B2401/00—Physical properties
- D10B2401/13—Physical properties anti-allergenic or anti-bacterial
-
- D—TEXTILES; PAPER
- D10—INDEXING SCHEME ASSOCIATED WITH SUBLASSES OF SECTION D, RELATING TO TEXTILES
- D10B—INDEXING SCHEME ASSOCIATED WITH SUBLASSES OF SECTION D, RELATING TO TEXTILES
- D10B2501/00—Wearing apparel
-
- D—TEXTILES; PAPER
- D10—INDEXING SCHEME ASSOCIATED WITH SUBLASSES OF SECTION D, RELATING TO TEXTILES
- D10B—INDEXING SCHEME ASSOCIATED WITH SUBLASSES OF SECTION D, RELATING TO TEXTILES
- D10B2501/00—Wearing apparel
- D10B2501/02—Underwear
-
- D—TEXTILES; PAPER
- D10—INDEXING SCHEME ASSOCIATED WITH SUBLASSES OF SECTION D, RELATING TO TEXTILES
- D10B—INDEXING SCHEME ASSOCIATED WITH SUBLASSES OF SECTION D, RELATING TO TEXTILES
- D10B2501/00—Wearing apparel
- D10B2501/02—Underwear
- D10B2501/021—Hosiery; Panti-hose
-
- D—TEXTILES; PAPER
- D10—INDEXING SCHEME ASSOCIATED WITH SUBLASSES OF SECTION D, RELATING TO TEXTILES
- D10B—INDEXING SCHEME ASSOCIATED WITH SUBLASSES OF SECTION D, RELATING TO TEXTILES
- D10B2501/00—Wearing apparel
- D10B2501/04—Outerwear; Protective garments
- D10B2501/041—Gloves
-
- D—TEXTILES; PAPER
- D10—INDEXING SCHEME ASSOCIATED WITH SUBLASSES OF SECTION D, RELATING TO TEXTILES
- D10B—INDEXING SCHEME ASSOCIATED WITH SUBLASSES OF SECTION D, RELATING TO TEXTILES
- D10B2503/00—Domestic or personal
-
- D—TEXTILES; PAPER
- D10—INDEXING SCHEME ASSOCIATED WITH SUBLASSES OF SECTION D, RELATING TO TEXTILES
- D10B—INDEXING SCHEME ASSOCIATED WITH SUBLASSES OF SECTION D, RELATING TO TEXTILES
- D10B2503/00—Domestic or personal
- D10B2503/06—Bed linen
-
- D—TEXTILES; PAPER
- D10—INDEXING SCHEME ASSOCIATED WITH SUBLASSES OF SECTION D, RELATING TO TEXTILES
- D10B—INDEXING SCHEME ASSOCIATED WITH SUBLASSES OF SECTION D, RELATING TO TEXTILES
- D10B2509/00—Medical; Hygiene
Abstract
A spunbonded non-woven fabric containing the cotton-linked scourge is prepared by improving the formula of polymer raw materials and the processing process of the polymer, and performing the working procedures of extrusion, stretching, bonding and the like by a conventional means. a. Preparing raw materials according to the parts by weight: 80-100 parts of ground calcium carbonate, 15-25 parts of corn starch, 1-2 parts of a surface treating agent, 3-7 parts of POE, 55-65 parts of polypropylene, 1-3 parts of polyisobutylene, 15-25 parts of honeysuckle antipyretic powder and 5-8 parts of essential oil; b. mixing heavy calcium carbonate, corn starch, honeysuckle plague-clearing powder and essential oil, and stirring uniformly at 35-40 ℃ until the water content is less than 2%; c. sequentially adding a surface treating agent, POE and polypropylene, uniformly stirring at 40-45 ℃, and standing at 50-55 ℃ for 8-12 hours to form a mixed powder material; d. and putting the mixed powder material and liquid polyisobutylene into an internal mixer for granulation, conveying the granules into a hot rolling double roller after prepressing by a hot pressing roller, rolling, pressing, binding, cooling and shaping to form the spunbonded non-woven fabric.
Description
Technical Field
The invention belongs to the technical field of preparation of spun-bonded non-woven fabrics, and relates to a preparation process of a spun-bonded non-woven fabric, in particular to a preparation process and application of a spun-bonded non-woven fabric containing double-flower antipyretic.
Background
The prior spun-bonded non-woven fabric has a mature process, namely, after prepared polymers are extruded and stretched to form continuous filaments, the filaments are laid into a web, and the web is subjected to self-bonding, thermal bonding, chemical bonding or mechanical reinforcement to change the web into the non-woven fabric. After many times of exploration, the process is continuously perfected. In the spun-bonded non-woven fabric process newly researched in recent years, the process parameters are adjusted and improved, so that the product finally achieves better quality, or the production efficiency is improved, and the like, and few people consider the new functions and new applications of the spun-bonded non-woven fabric. For example, patent application No. 201110207078.7 discloses a PP spunbonded nonwoven degradable composite material and a preparation process thereof, which mainly solves the problems of degradation and environmental protection of PP spunbonded nonwoven, and has no careless mistakes for new applications. For another example, patent application No. 201910822105.8 discloses a plant function PP spun-bonded nonwoven fabric and a preparation method thereof, which mainly solves the technical problems of air impermeability, too low moisture regain and rough hand feeling of the spun-bonded nonwoven fabric, and also provides a view on improving the product quality.
With the appearance and spread of globalized Xinguan pneumonia diseases, medical supplies such as masks, disinfection and sterilization aromatherapy products and the like become indispensable articles for people in daily life. Through a plurality of experiments, the Chinese herbal medicine ingredients are approved by the world to have resistance to the novel coronavirus. If the mask, the protective clothing and other medical care products can contain traditional Chinese medicine components, the novel coronavirus resistant mask is beneficial to human beings and harmless to human beings. However, it is the subject to be solved by the way that some medical care products such as a mask contain traditional Chinese medicine components.
The copperflower antipyretic capsule plays a key role in the treatment of the globularization new crown pneumonia disease, and most people accept that the copperflower antipyretic can resist new crown viruses. Therefore, many developers are thinking about applying the honeysuckle antipyretic to more medical care products. If the effective component of the lianhua scourge-clearing is applied to the spun-bonded non-woven fabric, the lianhua scourge-clearing effective component is used for preparing medical care products such as masks, protective clothing and the like, and the resistance of people to new coronavirus is improved absolutely. However, how to make the spunbonded nonwoven contain the effective components of the cotton-linked antipyretic has not been solved well by the preparation method.
Disclosure of Invention
The invention aims to solve the technical problem of how to prepare the spunbonded non-woven fabric containing the lingering scourge and designs a preparation process and application of the spunbonded non-woven fabric containing the lingering scourge.
The invention adopts the technical scheme that a preparation process of spunbonded non-woven fabric containing the honeysuckle scourge reduction is characterized in that: the process comprises the following steps:
a. preparing raw materials according to the parts by weight: 80-100 parts of ground calcium carbonate, 15-25 parts of corn starch, 1-2 parts of a surface treating agent, 3-7 parts of POE, 55-65 parts of polypropylene, 1-3 parts of polyisobutylene, 15-25 parts of honeysuckle antipyretic powder and 5-8 parts of essential oil;
b. mixing heavy calcium carbonate, corn starch, honeysuckle plague-clearing powder and essential oil, and stirring uniformly at 35-40 ℃ until the water content is less than 2%;
c. sequentially adding a surface treating agent, POE and polypropylene, uniformly stirring at 40-45 ℃, and standing at 50-55 ℃ for 8-12 hours to form a mixed powder material;
d. putting the mixed powder material and liquid polyisobutylene into an internal mixer for granulation;
e. the produced particles are subjected to the conventional procedures: screw rod melt extrusion, spinning machine extrusion fluid silk flow, silk flow cooling is led into drafting channel by negative pressure air flow to draft and elongate, and the drafted fiber strip is diffused and laid into net by diffusion plate and air flow diffusion effect, and is fed into hot rolling double roller after being prepressed by hot pressing roller, and is rolled, pressed, knotted and cooled to form spun-bonded non-woven fabric.
In the step a, the following raw materials are prepared according to the parts by weight: 85 parts of heavy calcium carbonate, 15 parts of corn starch, 1 part of surface treating agent, 4 parts of POE, 60 parts of polypropylene, 2 parts of polyisobutylene, 20 parts of Lianhua scourge powder and 7 parts of essential oil.
The particle diameter of the lianhua scourge-clearing powder is micron-sized or nano-sized.
The honeysuckle antipyretic powder comprises the following raw material medicines in parts by weight: 150-260 parts of fructus forsythiae, 150-260 parts of honeysuckle, 150-260 parts of isatis root, 30-55 parts of yellow, 50-90 parts of patchouli, 150-260 parts of rhizoma dryopteris crassirhizomae, 50-90 parts of rhodiola rosea, 5-8 parts of menthol, 50-90 parts of mix-fried ephedra, 50-90 parts of fried bitter almond, 150-260 parts of houttuynia cordata, 50-90 parts of liquorice and 150-260 parts of gypsum.
The honeysuckle antipyretic powder comprises the following raw material medicines in parts by weight: 255 parts of fructus forsythiae, 255 parts of honeysuckle, 255 parts of radix isatidis, 51 parts of rheum officinale, 85 parts of pogostemon cablin, 255 parts of male fern rhizome, 85 parts of rhodiola rosea, 7.5 parts of menthol, 85 parts of roasted ephedra, 85 parts of fried bitter almond, 255 parts of houttuynia cordata, 85 parts of liquorice and 255 parts of gypsum.
The spunbonded non-woven fabric containing the honeysuckle antipyretic prepared by the preparation method has the effects of anti-inflammation, antibiosis and antivirus.
The invention also relates to the preparation method and application of the spunbonded non-woven fabric containing the anti-flaming and anti-flaming effects in clothes, household textiles or medical protective products which are in contact with the skin.
The clothes contacted with the skin comprise underwear, underpants, a mask, socks, gloves and scarves.
The household textile comprises tablecloth, a bed sheet and bedding.
The medical protective product comprises a medical mask, a protective garment and a protective cap.
The process of the present invention comprises two major steps, the first step is the compounding and processing of the polymer, and the second step is the processing of the polymer. The key point of the invention is that the ingredients and processing of the polymer are improved, and the method must be used for comprehensively and uniformly adsorbing the anti-flaming blend powder and the polymer when the anti-flaming blend effective component is added, the essential oil can be used as a carrier of the anti-flaming blend powder, the anti-flaming blend powder is transferred into the polymer from the essential oil, and meanwhile, the anti-flaming blend powder can disappear through the subsequent treatment process, and has no influence on the production of the spun-bonded non-woven fabric.
The invention has the beneficial effects that through the proportioning and processing of the polymer raw materials, the final spun-bonded non-woven fabric contains the component for removing plague of the cotton rose, and the prepared spun-bonded non-woven fabric can have the functions of anti-inflammation, antibiosis and antivirus when being applied to clothes in contact with the skin, or household textiles or medical protective product products. Meanwhile, when the mask is applied to a mask, the mask can not only resist inflammation, bacteria and viruses, but also absorb water vapor around the mouth and nose, so that the breeding of bacteria and other complications are avoided. In addition, 68% of the effective component of the combined flower scourge remover can be attached to the spun-bonded non-woven fabric by the preparation process.
Detailed Description
The embodiments and effects of the present invention will be described in detail below with reference to specific examples.
The essential oil in the invention can be any one plant essential oil or the mixed essential oil of two or more than two plants.
The experimental process comprises the following steps: raw materials were prepared in parts by weight as provided in various examples in table 1;
table 1:
firstly, mixing heavy calcium carbonate, corn starch, honeysuckle antipyretic powder and essential oil, and uniformly stirring at 35 ℃ until the water content is less than 2%; adding the surface treating agent, POE and polypropylene in sequence, stirring uniformly at 43 ℃, and standing for 12 hours at 55 ℃ to form a mixed powder material.
Secondly, putting the mixed powder material and liquid polyisobutylene into an internal mixer for granulation; the produced particles are subjected to the conventional procedures: screw rod melt extrusion, spinning machine extrusion fluid silk flow, silk flow cooling is led into drafting channel by negative pressure air flow to draft and elongate, and the drafted fiber strip is diffused and laid into net by diffusion plate and air flow diffusion effect, and is fed into hot rolling double roller after being prepressed by hot pressing roller, and is rolled, pressed, knotted and cooled to form spun-bonded non-woven fabric.
The particle diameter of the lianhua scourge-clearing powder is micron-sized or nano-sized.
The 7 groups of non-woven fabric experimental products are obtained through the steps, the honeysuckle antipyretic is extracted by adopting ethanol, the honeysuckle antipyretic is weighed after extraction, and the results of the percentages of the honeysuckle antipyretic powder in the raw materials are shown in the table 2 and the table 2:
as can be seen from the performance table, example 4 is the most preferable scheme in the present invention, and can show that different ratios of raw materials have an influence on the adsorption performance of the modified spunbond nonwoven fabric.
The honeysuckle antipyretic powder comprises the following raw material medicines in parts by weight: 150-260 parts of fructus forsythiae, 150-260 parts of honeysuckle, 150-260 parts of isatis root, 30-55 parts of yellow, 50-90 parts of patchouli, 150-260 parts of rhizoma dryopteris crassirhizomae, 50-90 parts of rhodiola rosea, 5-8 parts of menthol, 50-90 parts of mix-fried ephedra, 50-90 parts of fried bitter almond, 150-260 parts of houttuynia cordata, 50-90 parts of liquorice and 150-260 parts of gypsum.
The honeysuckle antipyretic powder comprises the following raw material medicines in parts by weight: 255 parts of fructus forsythiae, 255 parts of honeysuckle, 255 parts of radix isatidis, 51 parts of rheum officinale, 85 parts of pogostemon cablin, 255 parts of male fern rhizome, 85 parts of rhodiola rosea, 7.5 parts of menthol, 85 parts of roasted ephedra, 85 parts of fried bitter almond, 255 parts of houttuynia cordata, 85 parts of liquorice and 255 parts of gypsum. The optimal formula proportion is selected in the function of preventing novel coronavirus, and the effect of the spunbonded non-woven fabric is improved.
The anti-inflammatory, antibacterial and antiviral experiments based on the honeysuckle antipyretic powder are as follows:
experimental subject: the influence of the honeysuckle antipyretic fever on acute inflammation and swelling of auricles of mice caused by xylene.
Purpose of experiment
Xylene, as a chemical inflammatory agent, can cause the release of certain inflammatory mediators, such as histamine, kinins, and fibrinolytic enzymes. The release of these mediators can cause increased local capillary permeability and infiltration of inflammatory cells, resulting in acute exudative inflammatory edema. In the experiment, a xylene-induced acute inflammation swelling model of mouse auricles is used, the inhibition rate of the honeysuckle extract on auricles swelling is observed, and the anti-inflammatory effect of the honeysuckle extract is researched.
1 materials of the experiment
1.1.1 test article 1
1.1.1 name: the intermediate dry paste powder of the lianhuaqingwen capsule is abbreviated as: LH-G.
1.1.2 physicochemical Properties: and (3) solid powder.
1.1.3 pseudo-clinical indications: resisting bacteria and inflammation.
1.1.4 content: 5.92g dry extract powder/g crude drug.
1.1.5 Source and batch number: shijiazhuang is provided by Ling pharmaceutical industries, Inc., lot number: 20160801.
1.1.6 storage of test article: and (4) keeping out of the sun, and ventilating at normal temperature.
1.2 Positive drugs, tool drugs and Main reagents
1.2.1 Positive drugs: dexamethasone, abbreviation: DEX, used for allergic and autoimmune inflammatory diseases. Tianjin Lisheng pharmaceutical products, Inc.
1.2.2 tool drugs and main reagents: 0.5% sodium carboxymethylcellulose (CMC-Na).
1.3 Experimental System
1.3.1 animal species: kunming (KM) mouse.
1.3.2 animal grades: SPF.
1.3.3 animal sex and number: 70, male.
1.3.4 animal ages: 4-5 weeks old.
1.3.5 animal weights: 18-22 g.
1.3.6 animal sources: is intended to be purchased from Beijing Wintonlihua laboratory animal technology Co.
1.3.7 raising conditions: the mice are bred in a new drug evaluation center of Ching medicine research institute Limited, Kyowa, Hebei under the condition of illumination for 12 hours/day, temperature of 20-26 ℃, relative humidity of 40-70%, and 5 mice are bred in a box. 1.3.8 quarantine process: the newly arrived animals were quarantined for at least 3 days, and during the quarantine the animals were observed for drinking, food intake, and health status, as well as the presence of signs of disease and death.
1.3.9 feed: a complete pellet feed for experimental animals is provided by Jiangsu cooperative pharmaceutical bioengineering, LLC.
1.3.10 padding: is planned to be purchased from Jiangsu cooperative medical bioengineering, LLC.
1.3.11 drinking water: purified water is prepared by an ROA50 experimental animal drinking system every day, drinking bottles are filled for animals to drink freely, and the drinking bottles are washed and changed once every day.
1.3.12 identifies: mice were marked with a marker.
2 method of experiment
2.1 experimental design basis
2.1.1 Using the Standard: the drug registration management method issued by the State food and drug administration, annex 2-chemical drug registration classification and declaration data requirement[1]。
2.2 dosage and formulation method
0.5% sodium carboxymethylcellulose (CMC-Na) solution: 1g of CMC-Na is dissolved in 200ml of pure water and heated until colorless and transparent.
Dexamethasone tablets: grinding 2.5mg dexamethasone 6 tablets into fine powder, suspending with 0.5% CMC-Na solution, metering to 9ml, with final concentration of 0.5mg/ml, and using as prepared before administration.
Lianhua antipyretic capsule powder: according to the clinical common adult dose of 0.8G/kg/d and the mouse administration dose of 10 times and 20 times of the human dose, the high and low doses of the Lianhua scourge LH-G are set to be 0.68G/kg and 1.35G/kg. 0.68G of LH-G and 1.35G of LH-G are weighed, ground in a mortar, dissolved in 0.5 percent CMC-Na solution and metered to 10 ml.
2.3 Experimental groups and administrations
70 mice were randomly divided into 7 groups: solvent control group, model control group, positive control group (dexamethasone 5mg/kg), LH-G (0.68G/kg, 1.35G/kg) high and low dose group, and 10 in one group. The solvent control group and the model control group were given the same volume of 0.5% CMC-Na solution for 7 days in succession. The experimental groups and dosages are given in table 3, according to the above dose setting principle.
TABLE 3 dose setting table of influence of flos coptidis extract on acute inflammation swelling of auricle of mouse caused by xylene
2.4 animal modeling
In the last administration, 50 mul of dimethylbenzene is dripped into the front and back of auricle of right ear of mouse and is evenly smeared, and the left ear is used as blank control without any treatment. Mice were sacrificed by cervical dislocation after 1h, round lugs were placed on the same portions of both ears of each mouse respectively by a punch with a diameter of 8mm, weighed, the degree of swelling was expressed by the difference in mass between the left and right lugs, and the swelling degree and inhibition rate of the ears of the mice were calculated.
Swelling degree of ear-the weight of inflamed-side ear-the weight of non-inflamed-side ear
The inhibition ratio is [ (average swelling degree of model control group-average swelling degree of administration group)/average swelling degree of model control group ] × 100%
2.5 related staff Notification
When the animal is bought, the animal room is informed, and when the animal is abnormal, the pathological room is informed to process.
2.6 statistical methods
The measurement data is represented by mean plus or minus standard deviation (x plus or minus s), SPSS 11.5 statistical software is adopted, firstly, the normality test is carried out, the data which accords with normal distribution is carried out, the one-factor analysis of variance is carried out, and if the variance is uniform, the Dunnett bilateral test is adopted; and carrying out appropriate variable conversion on the data which are not normal or uneven in variance, counting the converted data after the normal distribution or uniform variance requirement is met, and carrying out statistical analysis by adopting a rank sum test if the aim of normal distribution or uniform variance is not achieved after the variable conversion. The counting data is checked by chi-square.
3 results of the experiment
3.1 Effect of the extract of Nelumbo nucifera Gaertn on the degree of swelling of mouse ear caused by xylene
Compared with a normal control group, the ear swelling degree of the model group is obviously increased (P is less than 0.01). Compared with the model group, the positive control Dexamethasone (DEX) and LH-GG group obviously reduce the ear swelling of mice caused by dimethylbenzene (P is less than 0.01).
3.2 inhibition of mouse ear swelling by Paralichthys extract
The inhibition rate of ear swelling of DEX group is 32.90%, the inhibition rate of high and low dose of LH-G group is 36.96%, 27.37%, and the inhibition rate of high and low dose of LH-T group is 20.74%, 3.59%.
TABLE 4 Effect of extract of herba Lobeliae chinensis on acute inflammation swelling of auricle in mice caused by xylene
Note: comparison with normal control group:##p is less than 0.01; p < 0.05 compared to model group.
In conclusion, the honeysuckle antipyretic has an inhibiting effect on the swelling of inflammatory ears of mice caused by xylene, wherein the high-dose LH-GG group of the honeysuckle antipyretic extract-1 has an obvious inhibiting effect.
The following is a comparative test experiment of antibacterial, antiviral and anti-inflammatory effects of the spunbonded nonwoven containing the continuous flower scourge and the blank spunbonded nonwoven.
1. Antibacterial testing
GB/T20944.3-2008 oscillation method, washing 50 times with household double-tub washing machine, hanging and drying. The antibacterial rate of the patterned scourge-clearing spun-bonded non-woven fabric on staphylococcus aureus is 99%, the antibacterial rate on escherichia coli is 88%, the antibacterial rate on candida albicans is 83%, the antibacterial standard is met, and the antibacterial effect is achieved; the blank spun-bonded non-woven fabric has the bacteriostatic rate of 20 percent on staphylococcus aureus, 16 percent on escherichia coli and 18 percent on candida albicans, does not reach the bacteriostatic standard, has no bacteriostatic effect, and is shown in table 5.
TABLE 5 antibacterial Effect of Lianhua scour-clearing spun-bonded nonwoven and blank spun-bonded nonwoven
2. Antiviral testing
According to the test standard, the textile antiviral test standard ISO 18184:2014(E) is washed for 50 times under the laboratory condition, the antiviral activity rate of the anti-flaming spunbonding non-woven fabric for the H1N1 influenza A virus is as high as more than 99.9%, and the blank spunbonded non-woven fabric has no antiviral activity, and is shown in tables 6 and 7.
TABLE 6 influence of the Lianhua scour spun-bonded nonwoven on influenza A Virus H1N1
TABLE 7 influence of blank spunbonded nonwoven on influenza A Virus H1N1
3. Anti-inflammatory assay
Comparative test of lipopolysaccharide-induced RAW264.7 macrophage inflammation model by using combined-flower antipyretic spun-bonded non-woven fabric and blank spun-bonded non-woven fabric
3.1 Experimental materials
3.1.1 test article-Lianhua Qingwen spunbonded nonwoven and blank spunbonded nonwoven. Subjecting the sample to high-pressure moist heat sterilization at 115 deg.C for 15min based on 6cm2Ratio of/mL, 36cm2The test sample is subjected to shaking leaching at 60rpm for 24 +/-2 h in 6.0ml of cell culture solution at the temperature of 37 +/-1 ℃ to prepare test leaching liquor as the test sample.
3.1.2 Positive drugs, tool drugs and major reagent positive drugs: a dexamethasone standard; tool medicine and main reagent: LPS solution. Weighing l0 mg LPS, dissolving in conventional DMEM culture solution (containing 10% fetal calf serum, penicillin 100U ml-1, streptomycin 100 μ g. ml-1) to obtain 1mg/ml-1LPS solution, filtering with 0.22 μm microporous membrane for sterilization, packaging, and storing in refrigerator at 4 deg.C for use. 0.9% sodium chloride injection (normal saline); fetal bovine serum; DMEM culture solution; trypsin (0.25%); DMSO (assay pure).
3.2 test methods: effect on TNF-alpha release from RAW264.7 cells stimulated by LPS the concentration of RAW264.7 cells was adjusted to 2X 105/ml, 100. mu.l was inoculated into 96-well plates and incubated at 37 ℃ with 5% CO2And (3) incubating the cells in the incubator for 24 hours, adding 100 mu l of serum-free culture medium containing LPS (1 mu l/ml) and different drug-containing concentrations into each hole, arranging a normal control hole, a model hole and a positive control drug DEX (configured to be 10-5M in concentration), and taking cell culture supernatant after further incubating for 24 hours. The level of TNF-alpha secretion from RAW264.7 cells was measured according to the instructions of the TNF-alpha detection kit. The inhibition rate was (model TNF- α level-sample TNF- α level)/(model TNF- α level-control TNF- α level) × 100%.
3.3 test results
Compared with the normal group, the level of TNF-alpha released by RAW264.7 cells after LPS stimulation is remarkably increased in the model group (P is less than 0.01). Compared with the model group, the positive control group can obviously reduce the TNF-alpha level (P is less than 0.01), and the test substance Lianhua scourge spunbonded non-woven fabric leaching liquor can obviously reduce the TNF-alpha, has the inhibition rate of 54 percent and has the anti-inflammatory effect. Compared with the model group, the blank spunbonded non-woven fabric leaching liquor has no obvious influence on the TNF-alpha level, and no statistical difference is seen.
TABLE 8 influence of leaching liquor of spunbonded nonwoven fabric with flos Lonicerae and antipyretic on TNF-alpha release from RAW264.7 cells stimulated by LPS
Note: comparison with normal control group:##p is less than 0.01; comparing with model group, P < 0.01
The spunbonded non-woven fabric containing the continuous-pattern scourge reduction prepared by the invention can be widely applied to clothes contacted with skin, household textiles or medical protective products, including underwear, underpants, masks, socks, gloves, scarves, medical protective clothing, protective glasses and the like. Because the non-woven fabric contains the honeysuckle antipyretic component, clothes and medical protective products made of the non-woven fabric can slowly volatilize the honeysuckle antipyretic traditional Chinese medicine component, and the non-woven fabric is beneficial to improving the immunity of human bodies in life. The most obvious effect is that the mask is used in the mask. Some masks have replaceable inner cores, if the inner cores are made of non-woven fabrics containing the honeysuckle antipyretic, people can inhale the honeysuckle antipyretic during breathing, and the mask has excellent effects of improving the anti-inflammatory, antibacterial and antiviral abilities of human bodies. Meanwhile, when people carry a common mask for a long time, water vapor is generated at the edges and faces of the mouth when people exchange and breathe, and the water vapor can cause bacteria to grow and other complications are caused. If the mask contains the honeysuckle antipyretic, the honeysuckle antipyretic can absorb more water vapor and avoid bacterial breeding while improving the anti-inflammatory, antibacterial and antiviral abilities.
Claims (10)
1. A preparation process of spunbonded nonwoven containing cotton-linked plague removing is characterized by comprising the following steps: the process comprises the following steps:
a. preparing raw materials according to the parts by weight: 80-100 parts of ground calcium carbonate, 15-25 parts of corn starch, 1-2 parts of a surface treating agent, 3-7 parts of POE, 55-65 parts of polypropylene, 1-3 parts of polyisobutylene, 15-25 parts of honeysuckle antipyretic powder and 5-8 parts of essential oil;
b. mixing heavy calcium carbonate, corn starch, honeysuckle plague-clearing powder and essential oil, and stirring uniformly at 35-40 ℃ until the water content is less than 2%;
c. sequentially adding a surface treating agent, POE and polypropylene, uniformly stirring at 40-45 ℃, and standing at 50-55 ℃ for 8-12 hours to form a mixed powder material;
d. putting the mixed powder material and liquid polyisobutylene into an internal mixer for granulation;
e. the produced particles are subjected to the conventional procedures: screw rod melt extrusion, spinning machine extrusion fluid silk flow, silk flow cooling is led into drafting channel by negative pressure air flow to draft and elongate, and the drafted fiber strip is diffused and laid into net by diffusion plate and air flow diffusion effect, and is fed into hot rolling double roller after being prepressed by hot pressing roller, and is rolled, pressed, knotted and cooled to form spun-bonded non-woven fabric.
2. The process for preparing spunbonded nonwoven fabric containing established heat and pest control according to claim 1, which is characterized in that: in the step a, the following raw materials are prepared according to the parts by weight: 85 parts of heavy calcium carbonate, 15 parts of corn starch, 1 part of surface treating agent, 4 parts of POE, 60 parts of polypropylene, 2 parts of polyisobutylene, 20 parts of Lianhua scourge powder and 7 parts of essential oil.
3. The process for preparing spunbonded nonwoven fabric containing established heat and pest control according to claim 1, which is characterized in that: the particle diameter of the lianhua scourge-clearing powder is micron-sized or nano-sized.
4. The process for preparing spunbonded nonwoven fabric containing established heat and pest control according to claim 1, which is characterized in that: the honeysuckle antipyretic powder comprises the following raw material medicines in parts by weight: 150-260 parts of fructus forsythiae, 150-260 parts of honeysuckle, 150-260 parts of isatis root, 30-55 parts of yellow, 50-90 parts of patchouli, 150-260 parts of rhizoma dryopteris crassirhizomae, 50-90 parts of rhodiola rosea, 5-8 parts of menthol, 50-90 parts of mix-fried ephedra, 50-90 parts of fried bitter almond, 150-260 parts of houttuynia cordata, 50-90 parts of liquorice and 150-260 parts of gypsum.
5. The process for preparing spunbonded nonwoven fabric containing established heat and pest control according to claim 4, which is characterized in that: the honeysuckle antipyretic powder comprises the following raw material medicines in parts by weight: 255 parts of fructus forsythiae, 255 parts of honeysuckle, 255 parts of radix isatidis, 51 parts of rheum officinale, 85 parts of pogostemon cablin, 255 parts of male fern rhizome, 85 parts of rhodiola rosea, 7.5 parts of menthol, 85 parts of roasted ephedra, 85 parts of fried bitter almond, 255 parts of houttuynia cordata, 85 parts of liquorice and 255 parts of gypsum.
6. The production method according to any one of claims 1 to 5, characterized in that: the prepared spunbonded non-woven fabric containing the honeysuckle antipyretic has the effects of resisting inflammation, bacteria and viruses.
7. Use of the spunbonded nonwoven comprising the established scourge produced according to any one of the claims 1 to 5 for clothing, household textiles or medical protection which comes into contact with the skin.
8. Use according to claim 7, characterized in that: the clothes contacted with the skin comprise underwear, underpants, a mask, socks, gloves and scarves.
9. Use according to claim 7, characterized in that: the household textile comprises tablecloth, a bed sheet and bedding.
10. Use according to claim 7, characterized in that: the medical protective product comprises a medical mask, a protective garment and a protective cap.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011061798.2A CN112226905A (en) | 2020-09-30 | 2020-09-30 | Preparation process and application of spunbonded non-woven fabric containing honeysuckle antipyretic |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011061798.2A CN112226905A (en) | 2020-09-30 | 2020-09-30 | Preparation process and application of spunbonded non-woven fabric containing honeysuckle antipyretic |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112226905A true CN112226905A (en) | 2021-01-15 |
Family
ID=74120980
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011061798.2A Pending CN112226905A (en) | 2020-09-30 | 2020-09-30 | Preparation process and application of spunbonded non-woven fabric containing honeysuckle antipyretic |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112226905A (en) |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102336961A (en) * | 2011-07-23 | 2012-02-01 | 佛山市衡龙科技有限公司 | PP (Polypropylene) spun-bonded non-woven fabric degradable composite material and preparation process thereof |
| CN102884112A (en) * | 2010-05-04 | 2013-01-16 | 沙伯基础创新塑料知识产权有限公司 | Method of incorporating an additive into a polymer composition and dispersion used therein |
| CN103696141A (en) * | 2013-12-10 | 2014-04-02 | 马鞍山湖滨无纺布科技有限公司 | Healthcare non-woven fabric and preparation method thereof |
| US9192625B1 (en) * | 2011-07-01 | 2015-11-24 | Mangala Joshi | Antimicrobial nanocomposite compositions, fibers and films |
| CN109537166A (en) * | 2018-11-07 | 2019-03-29 | 桐城市鸿江包装有限公司 | The preparation method of antimicrobial form medical non-woven fabrics |
| CN111501211A (en) * | 2020-04-17 | 2020-08-07 | 百事基材料（青岛）股份有限公司 | Tea polyphenol, naringin or emodin modified PP spun-bonded non-woven fabric and preparation method thereof |
| CN111671179A (en) * | 2020-05-19 | 2020-09-18 | 南昌大学 | Mask accessory with double virus inactivation effects and preparation method thereof |
-
2020
- 2020-09-30 CN CN202011061798.2A patent/CN112226905A/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102884112A (en) * | 2010-05-04 | 2013-01-16 | 沙伯基础创新塑料知识产权有限公司 | Method of incorporating an additive into a polymer composition and dispersion used therein |
| US9192625B1 (en) * | 2011-07-01 | 2015-11-24 | Mangala Joshi | Antimicrobial nanocomposite compositions, fibers and films |
| CN102336961A (en) * | 2011-07-23 | 2012-02-01 | 佛山市衡龙科技有限公司 | PP (Polypropylene) spun-bonded non-woven fabric degradable composite material and preparation process thereof |
| CN103696141A (en) * | 2013-12-10 | 2014-04-02 | 马鞍山湖滨无纺布科技有限公司 | Healthcare non-woven fabric and preparation method thereof |
| CN109537166A (en) * | 2018-11-07 | 2019-03-29 | 桐城市鸿江包装有限公司 | The preparation method of antimicrobial form medical non-woven fabrics |
| CN111501211A (en) * | 2020-04-17 | 2020-08-07 | 百事基材料（青岛）股份有限公司 | Tea polyphenol, naringin or emodin modified PP spun-bonded non-woven fabric and preparation method thereof |
| CN111671179A (en) * | 2020-05-19 | 2020-09-18 | 南昌大学 | Mask accessory with double virus inactivation effects and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 彭成等: "《中国临床药物大辞典》", 30 November 2018 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113279146B (en) | Preparation process and application of spunbonded non-woven fabric containing extract of honeysuckle antipyretic | |
| CN101239160B (en) | Chinese medicine perfume composition and its sachet agent and fumigant | |
| CN102961469B (en) | Traditional Chinese medicine dispersible tablet for treating upper respiratory infection, and preparation method and quality detection method thereof | |
| CN111407817A (en) | Traditional Chinese medicine composition for preventing respiratory tract infection pathogenic microorganisms and preparation method thereof | |
| CN101628108B (en) | Traditional Chinese medicinal granules for treating wind-cold evil and preparation method thereof | |
| CN102441044B (en) | Care solution for wound cleaning | |
| CN102526573A (en) | Medicament for treating child cold | |
| CN102526578B (en) | Granular medicine for treating cold | |
| CN103301271B (en) | Tibetan medicine for treating pharyngitis and preparation method thereof | |
| CN112226905A (en) | Preparation process and application of spunbonded non-woven fabric containing honeysuckle antipyretic | |
| CN101104065B (en) | Traditional Chinese medicine preparation for preventing respiratory viral infection disease and preparation method | |
| CN103239570B (en) | Traditional Chinese medicinal ointment for treating infant diaper rash and preparation method thereof | |
| CN112176439A (en) | Preparation method and application of regenerated cellulose fiber containing honeysuckle antipyretic extract | |
| CN112226914A (en) | Preparation process and application of spun-bonded non-woven fabric containing traditional Chinese medicine extract | |
| CN101721437B (en) | Preparation method of medicine composition used for treating chronic pharyngitis | |
| CN106692630A (en) | Compound traditional Chinese medicine for preventing and treating stigmatosis of freshwater fish | |
| CN110684611A (en) | Antibacterial itching-relieving skin-moistening medicated soap using waste oil as soap base and preparation method thereof | |
| CN104758340B (en) | Coffee mesitoyl quinine acid extract and its preparation method and application in a kind of folium lonicerae | |
| CN103550360A (en) | Compound radix pulsatillae granule and preparation method thereof | |
| CN103599205B (en) | Traditional Chinese medicine liquid of control wound infection and preparation method thereof | |
| CN107692419A (en) | A kind of health care lavender suspension member and preparation method thereof | |
| CN107754001A (en) | A kind of feminine care non-woven fabrics for preventing and treating puerperal infection and its application | |
| CN108524614B (en) | Heat-clearing and dampness-eliminating powder and preparation method thereof | |
| CN108403866B (en) | Traditional Chinese medicine granule for preventing and treating avian influenza and improving chicken flock immunity and preparation method thereof | |
| CN112126997A (en) | Preparation method and application of regenerated cellulose fiber containing honeysuckle flower antipyretic |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210115 |